Ichnos Glenmark Innovation Inc (IGI), a clinical-stage biotechnology company focused on developing Multispecific therapeutics in oncology, announced on Tuesday the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for ISB 2301.
According to the company, ISB 2301 is a first-in-class, investigational multispecific immune cell activator designed to target three tumour-associated antigens and engage both T cells and NK cells. This pentaspecific molecule combines five binding specificities: three tumour-associated antigens, plus T-cell and NK-cell activation. By combining tumour-cell recognition with complementary immune activity, ISB 2301 is being developed to address biological heterogeneity and immune-suppressive features of solid tumours.
ISB 2301 was engineered using IGI's proprietary BEAT Multispecific Platform and is designed to recognise three tumour-associated antigens while engaging both T cells and NK cells through complementary mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), checkpoint inhibition, and the induction of a sustained type 1 immune response.
In preclinical studies, ISB 2301 demonstrated favourable pharmacokinetic and tolerability profiles in non-human primates, supporting the planned evaluation of its safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumour activity in patients with advanced solid tumours.
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
Specialised Therapeutics' YONDELIS sarcoma therapy approved in Thailand
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
PAI Pharma acquires Nexus Pharmaceuticals
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Guardant Health expands liquid biopsy test with AI-powered epigenomic applications
Nuvation Bio to present at Jefferies Global Healthcare Conference in London